CYH33 in Combination With Olaparib in Patients With Advanced Solid Tumors and DNA Damage Repair Mutations
Clinicaltrials.gov identifier:
NCT04586335
Advanced solid tumors
Study Contact Information:
MD Anderson Cancer Center
Contact: Sandra Montez, RN by phone: 713-745-6274 or by email.
or
Haihe Pharmaceuticals
Jason Sudia, PhD, MPH by email or Frank Tan, MD by email.
Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations
About the Study
This study is no longer recruiting patients.
This study will look at safety and effectiveness of the CYH33 combined with the olaparib in people with advanced cancers and a damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a . The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and can block tumor growth and overcome a patient’s resistance to treatment.
What the Study Entails
- Patients will receive CYH33 once per day orally in combination with 300 mg two times per day orally.
- Study participants will be followed for 38 months.
Type of Study
- This is an study. All participants will receive both CYH33 and . The study will enroll several different groups of people based on their tumor type and or genetic test results.
Study Site
Texas
Houston
MD Anderson Cancer Center
Contact: Sandra Montez, RN by phone: 713-745-6274 or by email.
Principal Investigator: Timothy Yap, MD
This study is no longer recruiting patients.
This study is no longer recruiting patients.